Biomedical Engineering Reference
In-Depth Information
Articles
Antibody technology
Benhar, I. 2001. Biotechnological applications of phage and cell display.
Biotechnology Advances
19
, 1-33.
Berger, M., Shankar, V., and Vafai, A. 2002. Therapeutic applications of monoclonal antibodies.
American Jour-
nal of the Medical Sciences
324
(1), 14 -30.
Chapman, P. 2002. PEGylated antibodies and antibody fragments for improved therapy: a review.
Advanced
Drug Delivery Reviews
54
(4), 531-545.
Dinnis, D. and James, D. 2005. Engineering mammalian cell factories for improved recombinant monoclonal
antibody production: lessons from nature?
Biotechnology and Bioengineering
91
(2), 180 -189.
Goldenberg, D. 2002. Targeted therapy of cancer with radiolabeled antibodies.
Journal of Nuclear Medicine
43
(5), 693-713.
He, M. and Khan, F. 2005. Ribosome display: next generation display technologies for production of antibodies
in vitro
.
Expert Review of Proteomics
2
(3), 421-430.
Hoogenboom, H.R., de Bruine, A.P., Hufton, S.E., Hoet, R.M., Arends, J.W., and Roovers, R.C. 1998. Antibody
phage display technology and its applications.
Immunotechnology
4
, 1-20.
Joshi, A., Bauer, R., Kuebler, P., White, M., Leddy, C., Compton, P., Garovoy, M., Kwon, P., Walicke, P., and
Dedrick, R. 2006. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal
antibody approved for use in psoriasis.
Journal of Clinical Pharmacology
46
(1), 10 -20.
Keating, G. and Perry, C., 2002. Infl iximab - an updated review of its use in Crohn's disease and rheumatoid
arthritis.
Biodrugs
16
(2), 111-148.
Kohler, G. and Milstein, C. 1975. Continuous culture of fused cells secreting antibody of pre-defi ned specifi city.
Nature
256
, 495-497.
Liossis, S. and Tsokos, G. 2005. Monoclonal antibodies and fusion proteins in medicine
. Journal of Allergy and
Clinical Immunology
116
(4), 721-729.
Longberg, N. 2005. Human antibodies from transgenic animals.
Nature Biotechnology
23
(9), 1117-1125.
McCarron, P.A., Olwill, S.A., Marouf, W.M.Y., Buick, R.J., Walker, B., and Scott, C.J. 2005. Antibody conjugates
and therapeutic strategies.
Molecular Interventions
5
(6), 368-380.
O'Mahony, D. and Bishop, M. 2006. Monoclonal antibody therapy.
Frontiers in Bioscience
11
, 1620-1635.
Schrama, D., Reisfeld, R.A., and Becker, J.C. 2006. Antibody targeted drugs as cancer therapeutics.
Nature
Reviews Drug Discovery
5
(2), 147-159.
Umemura, S., Sekido, Y., Itoh, H., and Osamura, R.Y. 2002. Pathological evaluation of HER2 overexpression for
the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab).
Acta
Histochemica et Cytochemica, Kyoto
35
(2), 77-81.
Walsh, G. 2004. Modern antibody-based therapeutics.
Biopharm International
17
, 18-25.
Wang, R. 1999. Human tumor antigens: implications for cancer vaccine development.
Journal of Molecular
Medicine
77
(9), 640-655.
Weiner, L. 2006. Fully human therapeutic monoclonal antibodies.
Journal of Immunotherapy
29
(1), 1-9.
Winter, G. and Milstein, C. 1991. Man-made antibodies.
Nature
349
, 293-299.
Vaccine technology
Andino, R., Silvera, D., Suggett, S.D., Achacoso, P.L., Miller, C.J., Baltimore, D., and Feinberg, M.B. 1994. Engi-
neering poliovirus as a vaccine vector for the expression of diverse antigens.
Science
265
, 1448-1451.
Bramwell, V. and Perrie, Y. 2005. The rational design of vaccines.
Drug Discovery Today
10
(22), 1527-1534.
Brewer, J. 2006. How do aluminium adjuvants work?
Immunology Letters
102
(1), 10 -15.
Cox, J. and Coutter, A. 1997. Adjuvants - a classifi cation and review of their modes of action.
Vaccine
15
(3),
248-256.
Search WWH ::
Custom Search